Mustang Bio Inc. (MBIO)
NASDAQ: MBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MBIO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.69M
- EPS (TTM)
- -$0.51
- Dividend yield
- None
- 52-week range
- 0.35 – 1.43
- Day range
- 0.3541 – 0.379
- Volume / Avg
- 84.29K / 33.87K
- Beta
- —
- Shares outstanding
- 6.74M
52-week range
MBIO stock today
On Nov 20, MBIO ended the session at $0.3541, shedding $0.0159 (4.30%), versus the S&P 500's 3.70% decline. Volume was 2.5x the average at 84.29K shares, a sign of unusually heavy trading. Shares are 75.2% below their 52-week high of $1.43 and 1.2% above the 52-week low of $0.35, near the bottom of the past year's range.
Mustang Bio has posted a net loss over the last twelve months (EPS of -$0.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mustang Bio
Company profileMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Manuel Litchman M.D.
- Headquarters
- Waltham, MA
- Employees
- 4
- Website
- mustangbio.com
Financial highlights
Full financialsMustang Bio reported a net loss of $1.9 million, compared with a loss of $15.8 million a year earlier. Diluted earnings per share came in at -$0.39.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-1.92M | $-15.75M | $-51.60M | $-77.53M | $-66.37M |
| EPS (diluted) | $-0.39 | $-38.57 | $-299.95 | $-10.09 | $-0.76 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 6, 2026
- EPS actual vs est.
- $-0.14 vs —
Mustang Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRAWTraws Pharma Inc. | 0.175 | -23.91% | $2.69M | vs MBIO |
| DRMADermata Therapeutics Inc. | 0.5095 | -4.23% | $2.51M | vs MBIO |
| RDHLRedhill Biopharma Ltd. ADR | 0.281 | -13.08% | $2.50M | vs MBIO |
| GRIGRI Bio Inc. | 1.12 | 0.00% | $2.45M | vs MBIO |
| APUSApimeds Pharmaceuticals US Inc. | 1.60 | -8.05% | $2.96M | vs MBIO |
| ONCOOnconetix Inc. | 2.89 | -8.54% | $2.37M | vs MBIO |
| HCWBHCW Biologics Inc. | 0.7491 | +1.90% | $2.35M | vs MBIO |
| JAGXJaguar Health Inc. | 0.227 | -30.58% | $3.03M | vs MBIO |
Indexes, lists and sector
Mustang Bio stock FAQ
What is Mustang Bio's stock price today?
MBIO last traded at $0.3541 as of Nov 20, 4:00 PM EST, down 4.30% on the day. Prices are delayed at least 15 minutes.
Who is Mustang Bio's CEO?
Dr. Manuel Litchman M.D. is the chief executive officer of Mustang Bio Inc., which has about 4 employees.
What is the MBIO 52-week high?
The 52-week high for MBIO is $1.43 and the 52-week low is $0.35. The stock is currently 75.2% below its high.